HUP0301830A3 - Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes - Google Patents

Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes

Info

Publication number
HUP0301830A3
HUP0301830A3 HU0301830A HUP0301830A HUP0301830A3 HU P0301830 A3 HUP0301830 A3 HU P0301830A3 HU 0301830 A HU0301830 A HU 0301830A HU P0301830 A HUP0301830 A HU P0301830A HU P0301830 A3 HUP0301830 A3 HU P0301830A3
Authority
HU
Hungary
Prior art keywords
diabetes
treatment
combination
pharmaceutical composition
composition containing
Prior art date
Application number
HU0301830A
Other languages
Hungarian (hu)
Original Assignee
Metabasis Therapeutics Inc
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc, Sankyo Co filed Critical Metabasis Therapeutics Inc
Publication of HUP0301830A2 publication Critical patent/HUP0301830A2/en
Publication of HUP0301830A3 publication Critical patent/HUP0301830A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
HU0301830A 2000-07-06 2001-07-05 Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes HUP0301830A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06
PCT/US2001/021557 WO2002003978A2 (en) 2000-07-06 2001-07-05 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES

Publications (2)

Publication Number Publication Date
HUP0301830A2 HUP0301830A2 (en) 2003-11-28
HUP0301830A3 true HUP0301830A3 (en) 2007-10-29

Family

ID=22807416

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301830A HUP0301830A3 (en) 2000-07-06 2001-07-05 Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes

Country Status (18)

Country Link
EP (1) EP1372660A2 (en)
JP (1) JP2004508297A (en)
KR (1) KR100854851B1 (en)
CN (2) CN100396283C (en)
AU (2) AU2001273271B2 (en)
BR (1) BR0112212A (en)
CA (1) CA2412142A1 (en)
CZ (1) CZ20035A3 (en)
HU (1) HUP0301830A3 (en)
IL (2) IL153513A0 (en)
MX (1) MXPA02012713A (en)
NO (1) NO20030034L (en)
NZ (1) NZ523227A (en)
PL (1) PL365779A1 (en)
RU (1) RU2328308C2 (en)
SK (1) SK62003A3 (en)
WO (1) WO2002003978A2 (en)
ZA (1) ZA200300044B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
EP1112275B9 (en) 1998-09-09 2004-03-10 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
CA2401706A1 (en) 2000-03-08 2001-09-13 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-bisphosphatase inhibitors
IL160983A0 (en) 2001-09-24 2004-08-31 Imp College Innovations Ltd Use of pyy for preparation of a medicament for modification of feeding behavior
CA2472882A1 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
AU2004309279B2 (en) 2003-12-26 2010-07-15 Kyowa Kirin Co., Ltd. Thiazole derivative
BRPI0514372A (en) * 2004-08-18 2008-06-10 Metabasis Therapeutics Inc fructose 1,6-bisphosphatase thiazole inhibitors
BRPI0519006A2 (en) * 2004-12-13 2008-12-23 Daiichi Sankyo Co Ltd use of a fbpase inhibitor, kit of a pharmaceutical composition, use of a biguanide preparation and a fbpase inhibitor, therapeutic agent for diabetes mellitus, and combination of therapeutic agents
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (en) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited Preparation produced by dry process
EP2089023A2 (en) 2006-11-02 2009-08-19 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with agonists of ppar-gamma
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
CN107312039B (en) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 A kind of preparation method of tenofovir prodrug
UY35065A (en) * 2012-10-08 2014-05-30 Lg Life Sciences Ltd COMBINED DRUG THAT INCLUDES GEMIGLIPTINE AND METFORMIN AND METHOD FOR PREPARATION
CN104788350A (en) * 2014-01-22 2015-07-22 天津大学 Method for acquiring medicinally-advantageous crystal form of tolbutamide through rapid cooling and crystallization
CN106831437B (en) * 2016-02-03 2019-06-21 华中师范大学 Ester type compound and its preparation method and application containing nitroethenyl group
CN114907285B (en) * 2021-02-10 2023-09-22 华中师范大学 Acylated saccharin compound, preparation method and application thereof, and hypoglycemic drug

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0427799B1 (en) * 1989-01-24 1994-11-30 Gensia, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
WO1998039342A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
ZA981936B (en) * 1997-03-07 1999-09-06 Metabasis Therapeutics Inc Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
WO1999047549A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
EP1112275B9 (en) * 1998-09-09 2004-03-10 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
DE69926400T2 (en) * 1998-12-24 2006-05-24 Metabasis Therapeutics Inc., San Diego COMPOSITION CONTAINING INSULIN-SENSITIVE ACTIVE SUBSTANCES AND INHIBITORS OF FRUKTOSE-1,6-BISPHOSPHATASE (FBPASE) FOR THE TREATMENT OF DIABETES
EP1741447B1 (en) * 2000-01-21 2013-09-18 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Also Published As

Publication number Publication date
WO2002003978A3 (en) 2003-10-16
PL365779A1 (en) 2005-01-10
JP2004508297A (en) 2004-03-18
NO20030034L (en) 2003-03-05
CN101301294A (en) 2008-11-12
BR0112212A (en) 2003-12-30
ZA200300044B (en) 2004-05-06
HUP0301830A2 (en) 2003-11-28
KR100854851B1 (en) 2008-08-27
CZ20035A3 (en) 2003-05-14
EP1372660A2 (en) 2004-01-02
SK62003A3 (en) 2003-09-11
IL153513A0 (en) 2003-07-06
CN100396283C (en) 2008-06-25
AU7327101A (en) 2002-01-21
MXPA02012713A (en) 2004-09-10
CN1599612A (en) 2005-03-23
AU2001273271B2 (en) 2006-01-05
IL153513A (en) 2014-07-31
CA2412142A1 (en) 2002-01-17
WO2002003978A2 (en) 2002-01-17
KR20030031952A (en) 2003-04-23
NO20030034D0 (en) 2003-01-03
RU2328308C2 (en) 2008-07-10
NZ523227A (en) 2005-04-29

Similar Documents

Publication Publication Date Title
HUP0301830A3 (en) Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
HUP0402236A3 (en) Heterocyclic compounds pharmaceutical compounds containing thereof and use thereof
IL188471A0 (en) Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
EP1389621A4 (en) N-substituted pyrazolyl-o-glycoside derivatives and remedial agent for diabetes containing the same
HUP0302485A3 (en) Arylmethylamine derivatives for use as tryptase inhibitors and pharmaceutical compositions containing them
HUP0102250A3 (en) Compounds of unstable dipeptidyl peptidase iv inhibitors, pharmaceutical compositions comprising thereof and their use
HUP0203965A3 (en) Indazole compounds and pharmaceutical compositions containing them
HUP0203939A3 (en) Pharmaceutical compounds and compositions containing them and their use
HUP0203700A3 (en) N-substituted 2-cyanopyrrolidines and their use as antidiabetic agents and pharmaceutical compositions containing them
HUP0200831A3 (en) Novel pharmaceutical composition containing amoxycillin and its use
HUP0203378A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
IL148517A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL150077A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
HUP0302950A3 (en) Synergistic herbicidal composition and a process for its use
HUP0102281A3 (en) Prodrugs of dipeptidyl peptidase iv inhibitors, pharmaceutical compositions comprising thereof and their use
IL143841A0 (en) Amide compounds and pharmaceutical compositions containing the same
HUP0402506A3 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
IL149883A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
HUP0400654A3 (en) Substituted 8-arylquinoline phosphodiesterase 4 inhibitors and pharmaceutical compositions containing them
HUP0204069A3 (en) Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
HUP0401612A3 (en) Pharmaceutical composition suitable for treating diabetes
HUP0200747A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
HUP0302397A3 (en) Heterocyclic compounds and pharmaceutical compositions containing them
EP1541139A4 (en) Drug composition containing nf-kappa b inhibitor
HUP0401862A3 (en) Novel heterocyclic compound and medicinal use thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees